Literature DB >> 6150981

Biotransformation of the topical glucocorticoids budesonide and beclomethasone 17 alpha,21-dipropionate in human liver and lung homogenate.

P Andersson, A Ryrfeldt.   

Abstract

Tritiated budesonide and beclomethasone 17 alpha,21-dipropionate (BDP) were incubated with the 9000g supernatant of human liver homogenate. BDP was immediately hydrolysed to beclomethasone 17 alpha-propionate (BMP). BMP was then further biotransformed to polar metabolites. Budesonide was rapidly biotransformed (2-4 times more rapidly than BMP) to metabolites of low glucocorticoid potency. The compounds were also incubated with the 1000g supernatant of human lung homogenate. BDP was rapidly hydrolysed to BMP and then more slowly to beclomethasone. Budesonide was not biotransformed in the lung.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6150981     DOI: 10.1111/j.2042-7158.1984.tb04868.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  15 in total

1.  Metabolism kinetics of beclomethasone propionate esters in human lung homogenates.

Authors:  K Foe; D J Cutler; K F Brown; J P Seale
Journal:  Pharm Res       Date:  2000-08       Impact factor: 4.200

Review 2.  Clinical pharmacokinetics of inhaled budesonide.

Authors:  R Donnelly; J P Seale
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

3.  Adrenal axis suppression unrelated to the dynamics of dosing with beclomethasone monopropionate.

Authors:  Siobhan A Mulrennan; Joseph S Hogg; Richard C Teoh; Alyn H Morice
Journal:  Br J Clin Pharmacol       Date:  2006-09-19       Impact factor: 4.335

4.  Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man.

Authors:  P T Daley-Yates; A C Price; J R Sisson; A Pereira; N Dallow
Journal:  Br J Clin Pharmacol       Date:  2001-05       Impact factor: 4.335

Review 5.  Safety of inhaled and intranasal corticosteroids: lessons for the new millennium.

Authors:  B J Lipworth; C M Jackson
Journal:  Drug Saf       Date:  2000-07       Impact factor: 5.606

Review 6.  Topical glucocorticoids with improved risk-benefit ratio. Rationale of a new concept.

Authors:  M Schäfer-Korting; M H Schmid; H C Korting
Journal:  Drug Saf       Date:  1996-06       Impact factor: 5.606

Review 7.  Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease.

Authors:  Staffan Edsbäcker; Tommy Andersson
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

8.  Unexpected side-effects of inhaled steroids: a case report.

Authors:  K Priftis; M L Everard; A D Milner
Journal:  Eur J Pediatr       Date:  1991-04       Impact factor: 3.183

Review 9.  Budesonide. A review of its pharmacological properties and therapeutic efficacy in inflammatory bowel disease.

Authors:  C M Spencer; D McTavish
Journal:  Drugs       Date:  1995-11       Impact factor: 9.546

10.  The gastrointestinal passage and release of beclomethasone dipropionate from oral delivery systems in ileostomy volunteers.

Authors:  J Burggraaf; A D van Haarst; P Fockens; H C Schoemaker; W J Krauwinkel; A F Cohen
Journal:  Br J Clin Pharmacol       Date:  1998-09       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.